Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new ...

(GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced ...

Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September ...

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only ...

The podcast draws on insights from recent industry data, regulatory updates, and the Company’s own developments, offering a fresh perspective on Izotropic’s mission and its flagship product, IzoView, ...

Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, filed a patent infringement lawsuit against Balt ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) and colleagues from multiple French ...

About VIVO ™ Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, ...

Nualtis (formerly IntelGenx Corp.), a leader in oral film drug delivery technologies, today announced a strategic partnership with OrthoNu LLC to develop and manufacture an innovative portfolio of ...

Belite Bio, Inc is a clinical stage drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as Stargardt ...

Financial Results for the Second Quarter and Six Months Ended June 30, 2025 Please note: All share amounts and per share amounts in this press release have been adjusted to reflect the 1-for-8 reverse ...

WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...